Sagimet Biosciences shares are trading higher after the company announced 52-week results from the Phase 3 ASC40-304 OLE trial of denifanstat for acne. The company suspended its at-the-market sale through Leerink Partners and announced the pricing of its $115 million offering of 8,750,010 shares at $10.00 per share.